Sleep apnea is a chronic condition characterised by recurrent interruptions in breathing throughout the sleep cycle. The two main forms are obstructive sleep apnea (OSA) and central sleep apnea (CSA).
OSA is distinguished by recurrent obstruction of the pharyngeal airway during sleep, resulting in reduced (hypopnea) or complete cessation (apnea) of airflow despite ongoing breathing efforts. These disruptions to breathing lead to intermittent oxygen desaturation, sleep disturbance, and sympathetic activation. When patients experience most of their apneic events in the supine sleep position, the term of positional obstructive sleep apnea (POSA) is used.
CSA is distinguished by repeated episodes of airflow reduction or interruption due to short decreases or pauses in central ventilatory drive during sleep. The symptoms are similar to OSA, although snoring and excessive weight may not be such prominent features.
Continuous positive airway pressure (CPAP) and adaptive servo-ventilation (ASV) are the main ways to prevent upper airway collapse and reduce CSA severity. OSA can also be treated using CPAP, oral devices or surgery and sleep position training devices are a good option for treating POSA.
To find out more about Sleep apnea visit our dedicated Learning Zone, which contains further information and clinical insights to help improve patient quality of life.
The goals of the task force were (1) to clarify and simplify the current scoring rules, (2) to review evidence for new monitoring technologies relevant to the scoring rules, and (3) to strive for greater concordance between adult and pediatric rules.
An update of the 2012 systematic review and meta-analyses were performed and a modified-GRADE approach was used to update the recommendation for the use of adaptive servo-ventilation (ASV) for the treatment of central sleep apnea syndrome (CSAS)...
Introduction: This guideline establishes clinical practice recommendations for positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA) in adults and is intended for use in conjunction with other American Academy...
Related news and insights
Jazz Pharmaceuticals plc announced the publication of the global Phase III double-blind, placebo-controlled, randomized-withdrawal, multicenter study of Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
Vanda Pharmaceuticals Inc. announced that following the completion of a Type A Meeting with the FDA on 8 May 2020, it has reached agreement with the FDA to resubmit its application for Hetlioz (tasimelteon) for the treatment of Smith-Magenis Syndrome (SMS). As previously disclosed, Vanda received a Refusal to File letter from the FDA on 12 March 2020.
Jazz Pharmaceuticals plc announced that the European Commission approved Sunosi (solriamfetol) to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).